Campochiaro et al. (2011) reported the six-month sustained benefits from Ranibizumab treatment for macular edema following CRVO. Aflibercept is a fusion protein that binds multiple isoforms of human VEGF-A, VEGF-B and placental growth factor (Heier et al., 2014). The gene discussed is VEGFA; the disease is macular retinal edema.